Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

clinical trial

Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD) is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT00847379

P6099clinical trial phasephase II clinical trialQ42824440
phase III clinical trialQ42824827
P17countryCanadaQ16
United States of AmericaQ30
SpainQ29
BelgiumQ31
ItalyQ38
SwedenQ34
GermanyQ183
FranceQ142
AustraliaQ408
United KingdomQ145
IsraelQ801
P582end time2010-05-01
P921main subjectBecker muscular dystrophyQ2484592
atalurenQ753330
P1132number of participants173
P6153research siteColumbia UniversityQ49088
University of MinnesotaQ238101
Katholieke Universiteit LeuvenQ833670
University of Utah Health CareQ56582915
Hospital Sant Joan de DéuQ64442914
Washington University in St. LouisQ777403
Alberta Children's HospitalQ2831698
Children's Hospital of Eastern OntarioQ2945735
Bambino Gesù HospitalQ3886684
Children's Hospital of PhiladelphiaQ4569202
Cincinnati Children's Hospital Medical CenterQ5120231
Duke University Medical CenterQ30279912
University of Kansas Medical CenterQ33526980
P580start time2009-01-01
P8363study typeinterventional studyQ78089383
P1476titleA Phase 2b Extension Study of Ataluren (PTC124) in Subjects With Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy

Search more.